Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
113.11
+0.95 (0.85%)
At close: May 4, 2026, 4:00 PM EDT
113.04
-0.07 (-0.06%)
After-hours: May 4, 2026, 7:59 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$876,907
Profits / Employee
$119,133
Market Cap
279.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
MRK News
- 9 hours ago - Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk - FXEmpire
- 4 days ago - Merck & Co. Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations - Business Wire
- 4 days ago - Merck Sales Rise on Continued Keytruda Growth - WSJ
- 4 days ago - Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook - CNBC
- 4 days ago - Merck posts quarterly loss due to Cidara charge, sales rise 5% - Reuters
- 4 days ago - Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones - Business Wire
- 6 days ago - Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke - Business Wire